Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Net Assets
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has net assets worth €39.81 Billion EUR (≈ $46.54 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€82.42 Billion ≈ $96.36 Billion USD) and total liabilities (€42.61 Billion ≈ $49.81 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Guangzhou Baiyunshan Pharmaceutical Hold's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €39.81 Billion |
| % of Total Assets | 48.3% |
| Annual Growth Rate | 16.53% |
| 5-Year Change | 33.91% |
| 10-Year Change | 334.94% |
| Growth Volatility | 27.03 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Net Assets Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets have evolved over time, based on quarterly financial data. Also explore Guangzhou Baiyunshan Pharmaceutical Hold assets under control for the complete picture of this company's asset base.
Annual Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
The table below shows the annual net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024. For live valuation and market cap data, see how much is Guangzhou Baiyunshan Pharmaceutical Hold worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €37.77 Billion ≈ $44.16 Billion |
+2.98% |
| 2023-12-31 | €36.68 Billion ≈ $42.88 Billion |
+9.04% |
| 2022-12-31 | €33.64 Billion ≈ $39.33 Billion |
+7.38% |
| 2021-12-31 | €31.33 Billion ≈ $36.62 Billion |
+11.07% |
| 2020-12-31 | €28.21 Billion ≈ $32.97 Billion |
+8.53% |
| 2019-12-31 | €25.99 Billion ≈ $30.38 Billion |
+12.30% |
| 2018-12-31 | €23.14 Billion ≈ $27.06 Billion |
+20.15% |
| 2017-12-31 | €19.26 Billion ≈ $22.52 Billion |
+9.12% |
| 2016-12-31 | €17.65 Billion ≈ $20.64 Billion |
+103.29% |
| 2015-12-31 | €8.68 Billion ≈ $10.15 Billion |
+9.62% |
| 2014-12-31 | €7.92 Billion ≈ $9.26 Billion |
+12.81% |
| 2013-12-31 | €7.02 Billion ≈ $8.21 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 614.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €21.82 Billion | 60.76% |
| Other Components | €14.09 Billion | 39.24% |
| Total Equity | €35.90 Billion | 100.00% |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Market Cap
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Kan Specialities Material Co Ltd
SHE:002012
|
$457.79 Million |
|
Doubleview Gold Corp
V:DBG
|
$457.81 Million |
|
Soft-World International
TWO:5478
|
$457.88 Million |
|
Zhejiang Golden Eagle Co Ltd
SHG:600232
|
$457.91 Million |
|
Golden Eagle Energy Tbk
JK:SMMT
|
$457.58 Million |
|
Daodaoquan Grain and Oil Co Ltd
SHE:002852
|
$457.53 Million |
|
Panoro Energy ASA
OL:PEN
|
$457.37 Million |
|
Csd Water Service Co Ltd
SHG:603903
|
$457.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,919,280,947 to 35,904,527,869, a change of 985,246,922 (2.8%).
- Net income of 2,835,496,164 contributed positively to equity growth.
- Dividend payments of 2,250,715,231 reduced retained earnings.
- Other factors increased equity by 400,465,990.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.84 Billion | +7.9% |
| Dividends Paid | €2.25 Billion | -6.27% |
| Other Changes | €400.47 Million | +1.12% |
| Total Change | €- | 2.82% |
Book Value vs Market Value Analysis
This analysis compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €11.61 | €1.78 | x |
| 2018-12-31 | €13.34 | €1.78 | x |
| 2019-12-31 | €14.88 | €1.78 | x |
| 2020-12-31 | €16.08 | €1.78 | x |
| 2021-12-31 | €17.88 | €1.78 | x |
| 2022-12-31 | €19.72 | €1.78 | x |
| 2023-12-31 | €21.48 | €1.78 | x |
| 2024-12-31 | €22.08 | €1.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.78%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 2.28x
- Recent ROE (7.90%) is below the historical average (12.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.35% | 5.57% | 1.44x | 1.79x | €296.87 Million |
| 2014 | 15.50% | 6.35% | 1.32x | 1.85x | €423.63 Million |
| 2015 | 15.39% | 6.80% | 1.21x | 1.88x | €455.27 Million |
| 2016 | 8.69% | 7.53% | 0.77x | 1.49x | €-226.48 Million |
| 2017 | 10.92% | 9.84% | 0.74x | 1.50x | €174.50 Million |
| 2018 | 15.87% | 8.15% | 0.82x | 2.37x | €1.27 Billion |
| 2019 | 13.19% | 4.91% | 1.14x | 2.35x | €770.40 Million |
| 2020 | 11.15% | 4.73% | 1.03x | 2.29x | €300.76 Million |
| 2021 | 12.80% | 5.39% | 1.04x | 2.28x | €813.66 Million |
| 2022 | 12.37% | 5.60% | 0.95x | 2.33x | €760.01 Million |
| 2023 | 11.61% | 5.37% | 0.96x | 2.25x | €563.75 Million |
| 2024 | 7.90% | 3.78% | 0.92x | 2.28x | €-754.96 Million |
Industry Comparison
This section compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $15,185,414,062
- Average return on equity (ROE) among peers: -13.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) | €39.81 Billion | 14.35% | 1.07x | $457.61 Million |
| AKSO HEALTH GR. (SPADR)/3 (8HX) | $12.29 Million | -137.16% | 4.11x | $1.60 Billion |
| EDAP TMS S.A (EDA) | $26.25 Million | -7.45% | 1.10x | $105.70 Million |
| Medios AG (ILM1) | $510.19 Million | 2.46% | 0.83x | $311.23 Million |
| M1 Kliniken AG (M12) | $29.75 Million | 22.29% | 0.12x | $300.08 Million |
| Paragon Care Limited (PXS) | $121.52 Million | 6.81% | 1.40x | $152.88 Million |
| Sigma Healthcare Limited (S5YA) | $477.77 Million | 0.38% | 1.46x | $18.92 Billion |
| TELES Informationstechnologien AG (TLIK) | $-13.19 Million | 0.00% | 0.00x | $2.22 Million |
| Sinopharm Group Co. Ltd (X2S) | $120.32 Billion | 7.52% | 2.19x | $3.15 Billion |
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more